Compare REKR & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REKR | NRXS |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 78.9M |
| IPO Year | 2017 | 2023 |
| Metric | REKR | NRXS |
|---|---|---|
| Price | $0.62 | $6.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.8M | 68.8K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.35 | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,234,000.00 | $3,569,282.00 |
| Revenue This Year | $12.51 | $172.91 |
| Revenue Next Year | $23.49 | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $0.55 | $2.20 |
| 52 Week High | $3.42 | $9.33 |
| Indicator | REKR | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 38.01 |
| Support Level | $0.60 | $5.50 |
| Resistance Level | $0.74 | $7.54 |
| Average True Range (ATR) | 0.05 | 0.36 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 44.78 | 33.56 |
Rekor Systems Inc is a roadway intelligence company focused on modernizing public safety, urban mobility, and transportation management through solutions. The company delivers services and solutions that collect, connect, and organize mobility data, providing real-time insights to support decision making, enhance situational awareness, enable rapid response, and support predictive analytics. The Company derives its revenues mainly from the licensing and sale of its roadway data and traffic management product and service offerings. These offerings include a mixture of data collection, implementation, engineering, customer support, and maintenance services, as well as software and hardware. The company operates in the United States and other regions.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).